Original Publication Date: 10 December, 2013
Publication / Source: Journal of Comparative Effectiveness Research
Authors: Jason Westin & Fredrick Hagemeister
Evaluation of: Cunningham D, Hawkes EA, Jack A et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a Phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880), 1817–1826 (2013). Therapy of newly diagnosed diffuse large B-cell lymphoma is largely unchanged for the past 30 years. Investigators have evaluated if modification of the schedule of drug administration may have a positive effect on outcomes.